Figure 2: Response to 3rd dose of mRNA vaccines (n=306).
Significant increase in anti-RBD IgG antibody level was observed between the last available pre-booster timepoint and the timepoint within the first month after the booster (****p<0.0001). The difference between the timepoint 2–4 weeks after the second dose and the timepoint within the first month after the booster was also significant (****p<0.0001). Month to month antibody decay is significant for the first 3 months after the booster, at which point the antibody level was still significantly higher than 2–4 weeks after the second dose (**p=0.0012).